AASTOCKS Financial News

HSI¹	22,671.86	-405.05	342.10B
HSCEI¹	7,460.84	-147.54	100.47B

Back Zoom + Zoom - Block Traded

CSPC PHARMA (01093.HK) Initiates Phase III Clinical Study in China for SYS6010 Combined with Enlangsubai Monoclonal Antibody for NSCLC Treatment
2026-06-26 18:00:27
CSPC PHARMA (01093.HK) announced that the Phase III clinical study in China of SYS6010 developed by the Group in combination with Enlangsubai Monoclonal Antibody for the treatment of driver gene-negative non-small cell lung cancer
(NSCLC) has been officially initiated. The first patient enrollment is planned to be completed in July this year. (sl/da)~

AASTOCKS Financial News
Website: www.aastocks.com

This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

(1) HK Indices are real time

Home|RT Quote|Market|News|Indices
Feedback

View: Mobile|Desktop
Lang: 繁|简|EN

Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.